Parenteral Levodopa and COMT Inhibitor Therapy for Parkinson's Motor Fluctuations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease using levodopa often result in motor fluctuations and dyskinesia due to pulsatile dopaminergic stimulation, and are limited by high peripheral levodopa concentrations leading to side effects.
Innovation Solution
A method involving the parenteral administration of a composition containing carbidopa and levodopa, concomitantly with oral administration of a catechol-O-methyl transferase (COMT) inhibitor such as entacapone or tolcapone, to achieve sustained levodopa levels in the brain while reducing peripheral side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa is administered to treat Parkinson's disease, then dopamine concentration in the brain is restored, but pulsatile dopaminergic stimulation occurs due to short half-life resulting in motor fluctuations and dyskinesia
Solution Approach 1:
The patent combines levodopa with carbidopa (a dopa decarboxylase inhibitor) and COMT inhibitors in a single formulation. The carbidopa preliminarily prevents peripheral conversion of levodopa to dopamine, while COMT inhibitors prevent alternative metabolic degradation. This preliminary protective action allows more levodopa to reach the brain unchanged, providing more stable and sustained dopaminergic stimulation without pulsatile fluctuations.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing three active ingredients: levodopa, carbidopa, and a COMT inhibitor (entacapone or tolcapone). This composite formulation works synergistically to extend levodopa's half-life, reduce peripheral metabolism, and maintain stable plasma concentrations, thereby eliminating motor fluctuations and dyskinesia while reliably restoring brain dopamine levels.
2Reliability
If large doses of levodopa are administered to overcome extracerebral metabolism, then brain dopamine concentration is restored, but high extracerebral concentrations of dopamine cause unwanted side effects
Solution Approach 1:
The patent extracts and blocks the harmful peripheral metabolic pathways by incorporating carbidopa (which inhibits dopa decarboxylase) and COMT inhibitors (which inhibit catechol-O-methyl transferase). These inhibitors selectively block levodopa metabolism in peripheral tissues while allowing levodopa to reach the brain, thereby extracting the harmful peripheral dopamine production and preventing side effects such as nausea, vomiting, and cardiovascular effects.
Solution Approach 2:
The carbidopa and COMT inhibitors act as intermediary protective agents that selectively prevent levodopa metabolism in peripheral tissues. These intermediaries allow levodopa to pass through the bloodstream unchanged to the brain, where it is then converted to dopamine by aromatic L-amino acid decarboxylase in the brain tissue. This intermediary protection eliminates the need for high levodopa doses and prevents peripheral side effects.
3Duration of action of stationary object
If sustained-release oral levodopa formulations are used, then treatment duration is extended, but efficacy is no more than standard tablets and motor complications persist
Solution Approach 1:
The patent fundamentally changes the pharmacokinetic parameters of levodopa by combining it with carbidopa and COMT inhibitors. This combination increases levodopa's plasma half-life from minutes to hours, transforms pulsatile concentration profiles into smooth sustained levels, and extends effective treatment duration beyond what sustained-release formulations alone can achieve. The parameter changes eliminate motor complications while maintaining extended duration of action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases blood levodopa levels by more than 40%, maintains constant levodopa levels, and reduces the initial levodopa dose, thereby minimizing side effects and improving treatment efficacy for Parkinson's disease.
Implementation Method 1
levodopa is usually administered concurrently with oral administration of a dopa decarboxylase inhibitor, such as carbidopa or benserazide, which reduces by 60-80% the levodopa dose required for a clinical response, and thus prevents certain of its side effects by inhibiting the conversion of levodopa to dopamine outside of the brain
Implementation Method 2
MAO inhibition by, e.g., moclobemide, rasagiline, selegiline or safinamide, or COMT inhibition by, e.g., entacapone or tolcapone, improves the efficacy of levodopa
Implementation Method 3
Levodopa (L-dopa or L-3,4-dihydroxyphenylalanine) is an immediate metabolic precursor of dopamine that, unlike dopamine, is able to cross the blood-brain barrier
Data Source
AI summary
The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.